Decreased susceptibility to cephalosporins among gonococci: data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales, 2007–2011

Ison, Catherine; Town, Katy; Obi, Chinelo; Chisholm, Stephanie; Hughes, Gwenda; Livermore, David M.; Lowndes, Catherine M

doi:10.1016/s1473-3099(13)70143-9

Cited by 129 publications

(126 citation statements)

References 20 publications

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…The dual-antimicrobial treatment regimens with ceftriaxone and azithromycin introduced in the United States (15) and Europe (17) appear to currently be highly effective and should be considered in all settings where comprehensive, quality-assured local AMR surveillance data are lacking or not clearly supporting any other treatment regimen (298,299). However, the susceptibility to ceftriaxone has been decreasing globally in recent years, resistance to azithromycin is prevalent in many settings and emerges rapidly in settings where this drug is frequently used, and gonococcal strains with decreased susceptibility or resistance to ceftriaxone and concomitant azithromycin resistance are already circulating globally.…”

Section: Future Perspectives For Treatmentmentioning

confidence: 99%

Antimicrobial Resistance in Neisseria gonorrhoeae in the 21st Century: Past, Evolution, and Future

2014

View full text Add to dashboard Cite

SUMMARY Neisseria gonorrhoeae is evolving into a superbug with resistance to previously and currently recommended antimicrobials for treatment of gonorrhea, which is a major public health concern globally. Given the global nature of gonorrhea, the high rate of usage of antimicrobials, suboptimal control and monitoring of antimicrobial resistance (AMR) and treatment failures, slow update of treatment guidelines in most geographical settings, and the extraordinary capacity of the gonococci to develop and retain AMR, it is likely that the global problem of gonococcal AMR will worsen in the foreseeable future and that the severe complications of gonorrhea will emerge as a silent epidemic. By understanding the evolution, emergence, and spread of AMR in N. gonorrhoeae , including its molecular and phenotypic mechanisms, resistance to antimicrobials used clinically can be anticipated, future methods for genetic testing for AMR might permit region-specific and tailor-made antimicrobial therapy, and the design of novel antimicrobials to circumvent the resistance problems can be undertaken more rationally. This review focuses on the history and evolution of gonorrhea treatment regimens and emerging resistance to them, on genetic and phenotypic determinants of gonococcal resistance to previously and currently recommended antimicrobials, including biological costs or benefits; and on crucial actions and future advances necessary to detect and treat resistant gonococcal strains and, ultimately, retain gonorrhea as a treatable infection.

show abstract

Section: Future Perspectives For Treatmentmentioning

confidence: 99%

Antimicrobial Resistance in Neisseria gonorrhoeae in the 21st Century: Past, Evolution, and Future

2014

View full text Add to dashboard Cite

show abstract

“…Reduced sensitivity to antimicrobial agents, particularly to fluoroquinolones and macrolides (259)(260)(261)(262) is a significant problem for some enteric pathogens and for STIs such as NG (263)(264)(265)and MG (145,266,267). Appropriate selection of antibiotics (antibiotic stewardship) is therefore required, based wherever possible on antibiotic susceptibility profiles.…”

Section: Neisseria Gonorrhoeaementioning

confidence: 99%

2016 United Kingdom national guideline on the sexual health care of men who have sex with men

et al. 2018

Self Cite

View full text Add to dashboard Cite

“…Since 2010, cefixime has not been recommended as first-line drug treatment [7,8] following WHO guidelines, stating that an antibiotic should not be used when more than 5 % of N. gonorrhoeae isolates are resistant [9]. Injectable ceftriaxone, in combination with oral azithromycin, are the recommended first line drug treatment [10]. Data regarding the epidemiology, prevalence of antibiotic resistance profile of N. gonorrhoeae in the cases of female infertility is scarce in Iran.…”

Section: Introductionmentioning

confidence: 99%

Antimicrobial susceptibility pattern of <i>Neisseria gonorrhoeae</i> isolated from fertile and infertile women

Azizmohammadi¹,

Azizmohammadi²

2017

Trop. J. Pharm Res

View full text Add to dashboard Cite

Decreased susceptibility to cephalosporins among gonococci: data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales, 2007–2011

Cited by 129 publications

References 20 publications

Antimicrobial Resistance in Neisseria gonorrhoeae in the 21st Century: Past, Evolution, and Future

Antimicrobial Resistance in Neisseria gonorrhoeae in the 21st Century: Past, Evolution, and Future

2016 United Kingdom national guideline on the sexual health care of men who have sex with men

Antimicrobial susceptibility pattern of <i>Neisseria gonorrhoeae</i> isolated from fertile and infertile women

Contact Info

Product

Resources

About